ResearcherWakkanai City HospitalNo recent work listed
Tetsuhito Muranaka
Matched on ORCID iD 0000-0002-5146-1451; OpenAlex author ID A5102260399. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper
Papers 3
- Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pa… Co-author DOI 10.3390/jcm12041596↗
- A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). Co-author DOI 10.1002/onco.13838↗
- Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. Co-author DOI 10.21037/jgo.2017.02.02↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yoshito Komatsu · 3 shared papers, 2017–2023 · strength 0.32
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Panc… DOI 10.1002/onco.13838↗
- Paper Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. DOI 10.21037/jgo.2017.02.02↗
- Yasuyuki Kawamoto · 3 shared papers, 2017–2023 · strength 0.32
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Panc… DOI 10.1002/onco.13838↗
- Paper Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. DOI 10.21037/jgo.2017.02.02↗
- Naoya Sakamoto · 3 shared papers, 2017–2023 · strength 0.32
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Panc… DOI 10.1002/onco.13838↗
- Paper Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. DOI 10.21037/jgo.2017.02.02↗
- Kazuaki Harada · 2 shared papers, 2021–2023 · strength 0.26
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Panc… DOI 10.1002/onco.13838↗
- Shintaro Nakano · 2 shared papers, 2021–2023 · strength 0.26
- Paper Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotec… DOI 10.3390/jcm12041596↗
- Paper A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Panc… DOI 10.1002/onco.13838↗
- Yuh Sakata · 1 shared paper, 2023 · strength 0.14
- Hideyuki Hayashi · 1 shared paper, 2021 · strength 0.12
- Masaki Kuwatani · 1 shared paper, 2017 · strength 0.06
- Kimitoshi Kubo · 1 shared paper, 2017 · strength 0.06
- Kazumichi Kawakubo · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.